Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

Maria Rinzivillo, Nicola Fazio, Sara Pusceddu, Andrea Spallanzani, Toni Ibrahim, Davide Campana, Riccardo Marconicini, Stefano Partelli, Giuseppe Badalamenti, Maria Pia Brizzi, Laura Catena, Giovanni Schinzari, Carlo Carnaghi, Rossana Berardi, Antongiulio Faggiano, Lorenzo Antonuzzo, Francesca Spada, Sara Gritti, Daniela Femia, Fabio GelsominoAlberto Bongiovanni, Sergio Ricci, Nicole Brighi, Massimo Falconi, Gianfranco Delle Fave, Francesco Panzuto

Research output: Contribution to journalArticle

Abstract

Introduction: Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty. Aim: To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting. Patients and methods: Retrospective analysis of progressive panNETs treated with sunitinib. Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th–75th IQR). Results: Eighty patients were included. Overall, 71.1% had NET G2, 26.3% had NET G1, and 2.6% had NET G3 neoplasms. A total of 53 patients (66.3%) had received three or more therapeutic regimens before sunitinib, with 24 patients (30%) having been treated with four previous treatments. Median PFS was 10 months. Similar risk of progression was observed between NET G1 and NET G2 tumors (median PFS 11 months and 8 months, respectively), and between patients who had received ≥ 3 vs ≤ 2 therapeutic approaches before sunitinib (median PFS 9 months and 10 months, respectively). DC rate was 71.3% and SD was the most frequent observed response, occurring in 43 pts (53.8%). Overall, 59 pts (73.8%) experienced AEs, which were grade 1–2 in 43 of them (72.9%), grade 3 in 15 pts (25.4%), and grade 4 in one patient (1.7%). Six pts (7.5%) stopped treatment due to toxicity. Conclusions: The present real-world experience shows that sunitinib is a safe and effective treatment for panNETs, even in the clinical setting of heavily pre-treated, progressive diseases.

Original languageEnglish
Pages (from-to)198-203
Number of pages6
JournalPancreatology
Volume18
Issue number2
DOIs
Publication statusPublished - Mar 1 2018

    Fingerprint

Keywords

  • Neuroendocrine tumors
  • Pancreas
  • Progressive disease
  • Sunitinib
  • Target therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Gastroenterology

Cite this

Rinzivillo, M., Fazio, N., Pusceddu, S., Spallanzani, A., Ibrahim, T., Campana, D., Marconicini, R., Partelli, S., Badalamenti, G., Brizzi, M. P., Catena, L., Schinzari, G., Carnaghi, C., Berardi, R., Faggiano, A., Antonuzzo, L., Spada, F., Gritti, S., Femia, D., ... Panzuto, F. (2018). Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 18(2), 198-203. https://doi.org/10.1016/j.pan.2018.01.005